Physician profile
Dacey Jo Wright
$6,865.23
in general payments reported to CMS, 2019-2025
9 companies · $6,429 in 2025
The $6,429 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $81.64 · 2024: $354 · 2025: $6,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,689 · Food and Beverage: $1,159 · Travel and Lodging: $940 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,688.75 |
| Food and Beverage | $1,158.95 |
| Travel and Lodging | $939.54 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Onmark, INC. | $6,016.93 | 2025 | |
| US Oncology Corporate, INC. | $230.74 | 2024 | |
| Janssen Biotech, INC. | $186.23 | 2023-2025 | Tecvayli, Darzalex, Talvey |
| Beone Medicines USA, INC. | $149.74 | 2025 | Brukinsa |
| Merck Sharp & Dohme LLC | $105.63 | 2024-2025 | Keytruda, Welireg, Reblozyl |
| Abbvie INC. | $89.90 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $45.55 | 2023 | Calquence |
| Genzyme Corporation | $21.61 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.90 | 2025 | Fruzaqla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dacey Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.